The U.S. Patent and Trademark Office (USPTO) has issued a new patent granting IP rights for the novel composition of matter and methods of use on the psilocybin-based molecules series EVM301 to its developer, Enveric Biosciences (NASDAQ: ENVB).
The biotech company is advancing next-generation, neuroplasticity-promoting psychoactive compounds to treat depression, anxiety and addiction disorders, including those covered by the patent.
Specifically, it provides Enveric with IP rights with claims to novel compositions and pharmaceutical drug formulations for a family of carboxylated derivatives of tryptamine-based drug candidates.
The company expects the patent to further ...